The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial [corrected] [published erratum appears in LANCET 2006 Oct 7-13;368(9543):1238].
| Autor: | Eron J Jr. (AUTHOR), Yeni P (AUTHOR), Gathe J Jr. (AUTHOR), Estrada V (AUTHOR), DeJesus E (AUTHOR), Staszewski S (AUTHOR), Lackey P (AUTHOR), Katlama C (AUTHOR), Young B (AUTHOR), Yau L (AUTHOR), Sutherland-Phillips D (AUTHOR), Wannamaker P (AUTHOR), Vavro C (AUTHOR), Patel L (AUTHOR), Yeo J (AUTHOR), Shaefer M (AUTHOR), KLEAN (Kaletra Versus Lexiva with Epivir and Abacavir in ART-Naive Patients) Study Team (CORPORATE AUTHOR) |
|---|---|
| Zdroj: | Lancet. 8/5/2006, Vol. 368 Issue 9534, p476-482. 7p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|